ZimVie Inc (ZIMV) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: -19.52%
• EPS Growth: 94.65%
• Country: US
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: N/A
• EPS (TTM): 0.26
• Shares Outstanding: N/A
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: 0.16
• Price to Book (P/B): 1.00
• Price to Sales (P/S): 0.85
• P/FCF Ratio: 51.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: $19.00 ▲(0.05% Upside)

ZimVie Inc.'s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. The technical analysis suggests bullish momentum, but overbought indicators may lead to a pullback. Valuation concerns, including a negative P/E ratio and lack of dividend yield, further weigh down the score.

Positive Factors

Improved Debt-to-Equity Ratio

An improved debt-to-equity ratio indicates better financial management and reduced leverage, enhancing long-term financial stability.

Stable Gross Profit Margin

A stable gross profit margin suggests effective cost management and operational efficiency, supporting long-term profitability.

Acquisition by ARCHIMED

The acquisition by ARCHIMED could provide strategic support and resources, potentially enhancing ZimVie's market position and growth prospects.

Negative Factors

Declining Revenue

Declining revenue trends indicate challenges in market demand or competitive positioning, impacting long-term growth potential.

Negative Cash Flow Growth

Negative cash flow growth highlights difficulties in cash generation, which can constrain investment and operational flexibility.

Persistent Losses

Ongoing losses reflect operational inefficiencies and market challenges, posing risks to long-term financial health and sustainability.

ZimVie Inc Business Overview & Revenue Model

Company Description

ZimVie Inc. (ZIMV) is a global medical technology company focused on providing solutions for spinal and dental implants. Established as a spin-off from Zimmer Biomet, ZimVie operates primarily in the orthopedic sector, developing innovative products for surgical procedures that enhance patient outcomes. The company's core offerings include a range of spinal implants, fixation devices, and dental prosthetics, which are designed to improve the quality of life for patients suffering from musculoskeletal disorders and dental issues.

How the Company Makes Money

ZimVie generates revenue primarily through the sale of its spinal and dental products to hospitals, clinics, and healthcare providers. The company has established a diversified revenue model that includes direct sales, partnerships with healthcare institutions, and collaborations with other medical device manufacturers. Key revenue streams are derived from product sales, which encompass both established and innovative solutions in the spinal and dental fields. Additionally, ZimVie benefits from ongoing relationships with surgeons and healthcare professionals, who often recommend its products due to their proven efficacy. The company may also engage in research and development partnerships, contributing to new product lines that can further enhance its earnings potential.

ZimVie Inc Financial Statement Overview

Summary

ZimVie Inc. faces ongoing challenges with revenue declines and profitability issues. Despite some improvement in cash flow and equity ratio, high leverage and negative margins present risks. The company needs to focus on improving operational efficiencies and revenue growth to enhance financial health.

Income Statement

ZimVie Inc. has struggled with declining revenues, from $1,014.6 million in 2021 to $443.6 million in TTM. The net profit margin is negative, indicating ongoing losses, though there is a slight improvement in EBITDA margin in TTM. This reflects challenges in maintaining both revenue levels and profitability.

Balance Sheet

The debt-to-equity ratio is relatively high at approximately 0.59 in TTM, indicating significant leverage. However, the equity ratio has improved to 52.97%, showing moderate financial stability. The company’s ROE remains negative, suggesting inefficiencies in generating returns on equity.

Cash Flow

The company has managed a positive free cash flow in TTM, although it has decreased from previous periods. Operating cash flow to net income ratio is not favorable due to negative net income, but cash flow management shows some resilience.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	443.40M	449.75M	457.43M	913.86M	1.01B	912.40M
Gross Profit	289.57M	287.45M	290.38M	613.08M	628.80M	599.50M
EBITDA	42.90M	29.61M	91.07M	79.16M	28.70M	-86.70M
Net Income	-19.47M	-25.82M	-393.28M	-63.88M	-95.30M	-179.00M
Balance Sheet
Total Assets	758.22M	753.67M	1.21B	1.64B	1.83B	1.95B
Cash, Cash Equivalents and Short-Term Investments	70.18M	74.97M	71.51M	89.60M	100.40M	27.40M
Total Debt	234.54M	232.57M	521.93M	564.14M	57.90M	89.20M
Total Liabilities	345.42M	371.97M	795.85M	883.45M	375.30M	458.70M
Stockholders Equity	412.80M	381.71M	409.49M	758.60M	1.45B	1.49B
Cash Flow
Free Cash Flow	5.62M	7.49M	24.66M	-1.92M	7.70M	47.70M
Operating Cash Flow	11.97M	14.17M	37.15M	24.63M	64.30M	86.00M
Investing Cash Flow	-12.78M	282.30M	-15.17M	-28.66M	-60.30M	-49.50M
Financing Cash Flow	-18.70M	-294.67M	-25.67M	-1.31M	72.30M	-46.50M

ZimVie Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.99
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZIMV, the sentiment is Positive. The current price of 18.99 is above the 20-day moving average (MA) of 18.96, above the 50-day MA of 18.93, and above the 200-day MA of 13.62, indicating a bullish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 74.81 is Negative, neither overbought nor oversold. The STOCH value of 75.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZIMV.

ZimVie Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVNS	―	$516.92M	―	-46.17%	―	1.48%	-6091.13%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OFIX	―	$610.98M	-4.87	-24.63%	―	4.84%	0.85%
BVS	―	$559.74M	―	-0.10%	―	5.08%	99.38%
BFLY	―	$513.55M	―	-29.42%	―	23.13%	46.62%
ZIMV	―	―	―	-4.76%	―	-19.52%	94.65%
KIDS	―	$413.02M	-8.42	-12.67%	―	19.90%	-57.90%

ZimVie Inc Corporate Events

ZimVie Inc Completes Acquisition by ARCHIMED

On October 20, 2025, ZimVie Inc. announced the completion of its acquisition by ARCHIMED, an investment firm focused on healthcare industries. As a result of the acquisition, ZimVie has become a privately held company, and its common stock is no longer traded on the NASDAQ stock exchange. ZimVie stockholders are entitled to receive $19.00 in cash per share. The acquisition is expected to accelerate ZimVie’s growth as a global leader in the dental implant market, with ARCHIMED providing strategic and financial support.

The most recent analyst rating on (ZIMV) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on ZimVie Inc stock, see the ZIMV Stock Forecast page.

ZimVie Inc Stockholders Approve Acquisition by ARCHIMED

On October 10, 2025, ZimVie Inc. announced that its stockholders approved the acquisition by an affiliate of ARCHIMED during a special meeting. The merger, which will result in ZimVie becoming a wholly owned subsidiary of ARCHIMED, is expected to close on October 20, 2025, leading to the delisting of ZimVie’s common stock from the Nasdaq Global Select Market.

The most recent analyst rating on (ZIMV) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on ZimVie Inc stock, see the ZIMV Stock Forecast page.

ZimVie Inc Faces Legal Challenges Over Merger

ZimVie Inc. announced a merger agreement with Zamboni Parent Inc., where ZimVie will become a wholly owned subsidiary of Zamboni. This merger is subject to stockholder approval and has led to legal challenges from stockholders alleging insufficient disclosures in the proxy statement. Despite these challenges, ZimVie plans to make supplemental disclosures to avoid delays and costs associated with litigation, while maintaining that the allegations are without merit.

The most recent analyst rating on (ZIMV) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on ZimVie Inc stock, see the ZIMV Stock Forecast page.

ZimVie Inc. Announces Stockholder Meeting for Merger Vote

On September 2, 2025, ZimVie Inc. announced a special meeting of stockholders scheduled for October 10, 2025, to vote on a merger agreement with Zamboni Parent Inc., an affiliate of ARCHIMED SAS. The merger, initially announced on July 20, 2025, proposes that ZimVie will become a wholly owned subsidiary of Zamboni Parent Inc., with stockholders receiving $19.00 per share. The board of directors has unanimously recommended the merger, citing it as fair and in the best interests of the company and its stockholders. The outcome of this merger could significantly impact ZimVie’s operations and market positioning.

The most recent analyst rating on (ZIMV) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on ZimVie Inc stock, see the ZIMV Stock Forecast page.

ZimVie Inc. Reports Q2 2025 Results Amid Acquisition

ZimVie Inc. is a global leader in the life sciences sector, specializing in dental implant solutions. The company is known for its comprehensive portfolio of products designed to support dental tooth replacement and restoration procedures, with a commitment to advancing clinical science and technology.